HIT TO MEDICAL MARIJUANA ‘ENDOCANNABINOID’ CROWD.
Lenabasum, an oral synthetic endocannabinoid-mimetic that preferentially binds to the cannabinoid receptor type 2 (CB2) fails to to sufficiently separate from placebo.
Imagine buying 10,000 shares on margin Friday. $90,000 ($45,000 equity) was worth $23,000 this morning. Since you still owe the house the $45,000 you borrowed – you are NEGATIVE $22,000.
Mix that with a Labor Day hangover. Plop, plop. fizz, fizz..
BIOTECH NIGHTMARES, THEY HAPPEN
WALL STREET’S BEST CAUGHT OFF GUARD. JUST A LITTLE
“Unprecedented improvement was observed in subjects on placebo added to background drug therapy!” What the?
‘We’re ahead of the pack’ in the Cannabinoid Drug Space, says CEO
We added Corbus to the Watch List last April – so close to a double! Adding Corbis Pharma (CRBP) $5.55 to Watch List.